InteKrin Overview
- Year Founded
-
2005
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5M
InteKrin General Information
Description
Developer of treatment of immune disorders designed to offer novel treatments that provide patients with better treatment alternatives. The company's immune disorder treatment includes INT131, a non-TZD peroxisome proliferator-activated receptor gamma modulator and focused on treating Relapsing Remitting Multiple Sclerosis, enabling physicians to meet the dual needs of neuroprotection and stopping the otherwise relentless progression of this devastating disease.
Contact Information
Website
www.intekrin.comCorporate Office
- 201 Redwood Shores Parkway
- Suite 200
- Redwood City, CA 94065
- United States
Corporate Office
- 201 Redwood Shores Parkway
- Suite 200
- Redwood City, CA 94065
- United States
InteKrin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 12-Feb-2014 | $5M | Completed | Clinical Trials - General | ||
| 6. Later Stage VC | 10-Jun-2010 | Completed | Startup | |||
| 5. Later Stage VC | 02-Apr-2009 | Completed | Startup | |||
| 4. Later Stage VC (Series C) | 10-Oct-2008 | Completed | Startup | |||
| 3. Early Stage VC | 19-Mar-2008 | Completed | Startup | |||
| 2. Early Stage VC | 11-Jan-2007 | $6.98M | $6.98M | Completed | Startup | |
| 1. Early Stage VC (Series A) | Completed | Startup |
InteKrin Comparisons
Industry
Financing
Details
InteKrin Competitors (48)
One of InteKrin’s 48 competitors is Argos Therapeutics, a Venture Capital-Backed company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Argos Therapeutics | Venture Capital-Backed | Durham, NC | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
InteKrin Patents
InteKrin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017326261-A1 | Treatment of multiple sclerosis with chs-131 | Inactive | 13-Sep-2016 | ||
| CA-3036694-A1 | Treatment of multiple sclerosis with chs-131 | Inactive | 13-Sep-2016 | ||
| EP-3512512-A1 | Treatment of multiple sclerosis with chs-131 | Inactive | 13-Sep-2016 | ||
| EP-3512512-A4 | Treatment of multiple sclerosis with chs-131 | Inactive | 13-Sep-2016 | ||
| US-20190224186-A1 | Treatment of multiple sclerosis with chs-131 | Inactive | 13-Sep-2016 | A61K31/47 |
InteKrin Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amgen | Corporation | Minority | ||
| Asset Management Ventures | Venture Capital | Minority | ||
| Hunt BioVentures | Venture Capital | Minority | ||
| Lanfear Capital | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority |
InteKrin FAQs
-
When was InteKrin founded?
InteKrin was founded in 2005.
-
Where is InteKrin headquartered?
InteKrin is headquartered in Redwood City, CA.
-
What industry is InteKrin in?
InteKrin’s primary industry is Drug Discovery.
-
Is InteKrin a private or public company?
InteKrin is a Private company.
-
What is the current valuation of InteKrin?
The current valuation of InteKrin is .
-
What is InteKrin’s current revenue?
The current revenue for InteKrin is .
-
How much funding has InteKrin raised over time?
InteKrin has raised $73.9M.
-
Who are InteKrin’s investors?
Amgen, Asset Management Ventures, Hunt BioVentures, Lanfear Capital, and OrbiMed are 5 of 10 investors who have invested in InteKrin.
-
Who are InteKrin’s competitors?
Argos Therapeutics, Xalud Therapeutics, Centrexion Therapeutics, Inovio Pharmaceuticals, and Rein Therapeutics are some of the 48 competitors of InteKrin.
-
When was InteKrin acquired?
InteKrin was acquired on 12-Feb-2014.
-
Who acquired InteKrin?
InteKrin was acquired by Coherus Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process